Yahoo
Tokyo - Delayed Quote JPY

Cuorips Inc. (4894.T)

6,460.00 +410.00 (+6.78%)
At close: 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 4894.T
  • Previous Close 6,050.00
  • Open 6,290.00
  • Bid 6,460.00 x --
  • Ask 6,470.00 x --
  • Day's Range 6,260.00 - 6,580.00
  • 52 Week Range 3,610.00 - 12,400.00
  • Volume 108,600
  • Avg. Volume 145,201
  • Market Cap (intraday) 57.354B
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) -138.33
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets in Japan. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Osaka, Japan.

cuorips.co.jp

51

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4894.T
7.13%
Nikkei 225 (^N225)
16.76%

1-Year Return

4894.T
0.62%
Nikkei 225 (^N225)
16.90%

3-Year Return

4894.T
303.75%
Nikkei 225 (^N225)
80.04%

5-Year Return

4894.T
284.52%
Nikkei 225 (^N225)
100.70%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 15M
Earnings -249M
Profit Margin -1,660.00%

Q1

FY25

Q3

FY25

Q1

FY26

Q3

FY26

-200M
-100M
0
-1500.0%
-1000.0%
-500.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.41%

  • Return on Equity (ttm)

    -23.28%

  • Revenue (ttm)

    128M

  • Net Income Avi to Common (ttm)

    -1.14B

  • Diluted EPS (ttm)

    -138.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.32B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: